WuXi Biologics has acquired 3 companies, including 3 in the last 5 years.
The Company’s most targeted sectors include life science (100%).
No. 108, Meiliang Road, Mashan Binhu District,
Wuxi,
214092
China,
www.wuxibiologics.com.cn
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2021-05-07 |
CMAB Biopharma · Life Science
Suzhou, China · www.cmabbio.com CMAB Biopharma is a full-service contract development and manufacturing organization (CDMO) dedicated to providing process development and manufacturing services for biologic products. The company provides bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Its adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical products today. CMAB Biopharma was formed in 2017 and is based in Suzhou, China. |
- | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
